Jia-Ye Hua1, Xu-Hong Zhou, Shu-Ting Ouyang, Yong-Bin Wu. 1. Department of Hematology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China. E-mail: jy1016aa@163.com.
Abstract
OBJECTIVE: To investigate the effect of bortezomib in inducing apoptosis in imatinib-resistant K562 (K562R) cells and its possible mechanism. METHODS: K562 cells were cultured in gradient concentrations of imatinib for several months to generate imatinib-resistant K562 cells. The viability of K562R cells treated with bortezomib was measured using CCK-8 cell proliferation assay, and the cell apoptosis was analyzed by flow cytometry with annexin V/PI dual staining. Western blotting was used to detect the protein expressions of Mcl-1,Bcl-2 and Bcr/Abl. RESULTS: K562R cell line was successfully established, which showed 31.8 folds of imatinib resistance compared with the na?ve cells. Bortezomib treatment produced dose- and time-dependent inhibitory effect on the proliferation of both K562 cells and K562R cells and dose-dependently induced apoptosis in K562R cells. Combination of bortezomib with imatinib significantly enhanced the apoptosis of the cells. Western blotting showed that bortezomib treatment dose-dependently decreased the protein levels of both Mcl-1and Bcr/Abl in K562R cells without affecting bcl-2 protein expression. CONCLUSION: Bortezomib can inhibit the proliferation of K562R cells and induce cell apoptosis possibly by down-regulating Mcl-1 and Bcr/Abl expression and enhancing Mcl-1 cleavage.
OBJECTIVE: To investigate the effect of bortezomib in inducing apoptosis in imatinib-resistant K562 (K562R) cells and its possible mechanism. METHODS: K562 cells were cultured in gradient concentrations of imatinib for several months to generate imatinib-resistant K562 cells. The viability of K562R cells treated with bortezomib was measured using CCK-8 cell proliferation assay, and the cell apoptosis was analyzed by flow cytometry with annexin V/PI dual staining. Western blotting was used to detect the protein expressions of Mcl-1,Bcl-2 and Bcr/Abl. RESULTS: K562R cell line was successfully established, which showed 31.8 folds of imatinib resistance compared with the na?ve cells. Bortezomib treatment produced dose- and time-dependent inhibitory effect on the proliferation of both K562 cells and K562R cells and dose-dependently induced apoptosis in K562R cells. Combination of bortezomib with imatinib significantly enhanced the apoptosis of the cells. Western blotting showed that bortezomib treatment dose-dependently decreased the protein levels of both Mcl-1and Bcr/Abl in K562R cells without affecting bcl-2 protein expression. CONCLUSION:Bortezomib can inhibit the proliferation of K562R cells and induce cell apoptosis possibly by down-regulating Mcl-1 and Bcr/Abl expression and enhancing Mcl-1 cleavage.
Authors: Yongbin Wu; Chun Chen; Xiaoyong Sun; Xianping Shi; Bei Jin; Ke Ding; Sai-Ching Jim Yeung; Jingxuan Pan Journal: Clin Cancer Res Date: 2012-03-23 Impact factor: 12.531
Authors: Rong Chen; William G Wierda; Sherri Chubb; Rachael E Hawtin; Judith A Fox; Michael J Keating; Varsha Gandhi; William Plunkett Journal: Blood Date: 2009-02-20 Impact factor: 22.113
Authors: Simona Gatto; Barbara Scappini; Lan Pham; Francesco Onida; Michele Milella; Greg Ball; Clara Ricci; Vladimir Divoky; Srdan Verstovsek; Hagop M Kantarjian; Michael J Keating; Jorge E Cortes-Franco; Miloslav Beran Journal: Haematologica Date: 2003-08 Impact factor: 9.941
Authors: Denis O Okumu; Michael P East; Merlin Levine; Laura E Herring; Raymond Zhang; Thomas S K Gilbert; David W Litchfield; Yanping Zhang; Lee M Graves Journal: PLoS One Date: 2017-05-16 Impact factor: 3.240
Authors: Ahmad Iskandarani; Ajaz A Bhat; Kodappully S Siveen; Kirti S Prabhu; Shilpa Kuttikrishnan; Muzammil A Khan; Roopesh Krishnankutty; Michal Kulinski; Rihab R Nasr; Ramzi M Mohammad; Shahab Uddin Journal: J Transl Med Date: 2016-03-09 Impact factor: 5.531